In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on Clearside Biomedical (CLSD - Research Report), with a price target of $9.00. The company's shares opened today at $1.65.According to TipRanks, Argyrides is a 2-star analyst with an average return of 1.3% and a 41.67% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Global Blood Therapeutics, and Clearside Biomedical.Currently, the analyst consensus on Clearside Biomedical is a Strong Buy with an average price target of $7.67, representing a 364.85% upside. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $9.00 price target.
https://www.tipranks.com/news/blurbs/clearside-biomedical-clsd-receives-a-buy-from-wedbush?utm_source=advfn.com&utm_medium=referral
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Clearside Biomedical Charts.
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Clearside Biomedical Charts.